Proscia, a provider of digital and computational pathology solutions, announced that Spectrum Healthcare Partners (SHCP), an independent, multispecialty, physician-owned healthcare practice, has selected Concentriq Dx to modernize its pathology operations.
In adopting Proscia’s software platform, SHCP will increase access to high-quality diagnostic services across Maine and New Hampshire, better informing treatment decisions for more patients, the company says.
Digital pathology is democratizing diagnostic services for diseases like cancer at a time when an intensifying workforce shortage is putting added pressure on laboratories to keep pace with rising biopsy volume. As SHCP serves patients across various healthcare systems, it recognized an opportunity to pioneer the use of digital pathology in its region to expand the reach of its subspecialist experts and deliver timely results.
“We believe that all patients, regardless of geography, deserve access to high quality care,” says Bilal R. Ahmad, MD, MBA, FCAP, managing director, Pathology Division at Spectrum Healthcare Partners. “Concentriq Dx is critical to decentralizing our diagnostic services. It will enable us to seamlessly transition to digital pathology at scale so that we can reimagine our day-to-day operations beyond the confines of our physical laboratory spaces.”
Concentriq Dx* is a modern digital pathology platform that drives diagnostic workflows for laboratory networks of all sizes. By streamlining collaboration and enabling remote image viewing, it provides faster, broader access to subspecialist experts, helping more patients to begin treatment sooner. The platform also offers interoperability with leading scanners and image analysis applications, according to the company.
“We are excited to welcome Spectrum Healthcare Partners to the growing roster of hospital systems and diagnostic laboratories adopting Concentriq Dx,” says David West, Proscia’s CEO. “Our organizations share a strong commitment to the patient, and we are thrilled that SHCP sees the value of modern digital pathology in democratizing diagnosis and helping to improve treatment decisions.”
*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.